SFRP2 and colorectal carcinoma: Another meta-analysis, conducted by Shariatpanahi et al., found that promoter methylation of SFRP2 in stool samples was associated with an increased risk of CRC (OR = 35.3 [18.7–66.8], AUC = 0.94) [9], indicating its potential use as a diagnostic biomarker.